WASHINGTON (MedPage Today) —A novel subcutaneous implantable cardioverter-defibrillator has met the primary safety and effectiveness endpoints,but questions remain regarding safety and efficacy,according to FDA staff reviewers.
MedPageToday.com –medical news plus CME for physicians












































